Liver Cancer Treatment Paradigm Undergoing Major Overhaul
Christine Lehmann, MA
Published Online: Oct 15,2018
Until recently, few systemic therapies had been approved for the treatment of patients with liver cancer, as few agents could demonstrate significant benefit over placebo. Sorafenib (Nexavar) was the first systemic therapy that extended median overall survival (OS) over placebo by nearly 3 months (10.7 versus 7.9 months),1 and, in December 2007, it became the first systemic therapy approved by the FDA for patients with unresectable hepatocellular carcinoma (HCC).
Read the article:
https://www.targetedonc.com/publications/targeted-therapy-news/2018/oct-2018/liver-cancer-treatment-paradigm-undergoing-major-overhaul
Free registration may be required
Free registration may be required
No comments:
Post a Comment